Drugs / OMA102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05824065 | Jan 2025 → Jan 2027 expected | androgenetic alopecia | EMS | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMA102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05824065 ↗ |
| Route | Oral | “Ingestion of 1 oral tablet, once a day, immediately before lying down to sleep” NCT05824065 ↗ |